Please assess the completion status of the following clinical trial:

Trial Title: Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* JRA by American College of Rheumatology (ACR) criteria - Active joints - Initiate etanercept alone, etanercept plus methotrexate or other DMARDs, methotrexate alone, or methotrexate with other DMARDs within 6 months of entry into Registry~* Polyarticular or systemic RA in 3 or more joints at start of treatment

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Methotrexate group (Type: None): Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.

Based on this trial design, predict the completion outcome and termination type (if applicable).